ASSOCIATION OF SINGLE NUCLEOTIDE VARIANTS IN THE DRD3 AND LINGO1 GENES WITH THE DEVELOPMENT OF DRUG DYSKINESIAS IN PARKINSON'S DISEASE: RESULTS OF A PILOT STUDY

Levodopa is the "gold" standard of pharmacotherapy for Parkinson's disease (PD). Levodopa has its own advantages, such as high efficiency at all stages of the disease, low incidence of side effects, availability, at the same time, long-term levodopa therapy is associated with the development of levodopa-induced dyskinesias (LID). Approximately one third of patients in the fifth year of illness already have LID; by the 10th year of illness, almost all patients have this disorder. LID can be associated with gene polymorphisms, the products of which are involved in the metabolism of levodopa. The aim was to study the association of single nucleotide variants (SNV) rs6280 (DRD3 gene) and rs9652490 (LINGO1 gene) with the development LID in PD. The study included 47 patients with PD, 21 (44.7%) men and 26 (55.3%) women. The average age was 69.0 +/- 7.67 years. Patients with a mixed form of PD predominated (72.3%). The average duration of the disease was 5.94 +/- 4.09 years. Results. Patients with PD in both groups (with and without LID) did not differ in age, gender and ethnicity, stage of disease, non-motor symptoms, and degree of cognitive impairment. At the same time, patients with LID showed frequent development of motor fluctuations, a longer duration of levodopa therapy, and a higher levodopa equivalent daily dose. Analysis of the effect of DRD3 (Ser9Gly, or rs6280) and LINGO1 (rs9652490) polymorphisms on the development of LID in PD was not found. Conclusion. The results of a pilot study indicate the absence of a predictive role of the carriage of SNV rs6280 (DRD3 gene) and rs9652490 (LINGO1 gene) on the development of LID in PD patients living in the Republic of Sakha (Yakutia). However, the authors do not exclude the influence of a small sample size on the results of the associative genetic study.